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licenses/by/4.0/).Abstract Background: The incidence and clinical significance of electrolyte abnormalities
(EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the inci-
dence and severity of EAs, graded according to CTCAE, v4.03, to identify variables associated
with EAs and their prognostic significance in a phase I population.
Methods: A retrospective chart review was performed of 1088 cases in 82 phase I clinical trials
consecutively treated from 2011 to 2015 at the Drug Development Unit of the Royal Marsden
Hospital. Cox regression analysis was performed to examine the relationship between overall
survival (OS) and baseline characteristics, treating the occurrence of grade III/IV EAs as a
time-varying covariate.
Results: The most common emergent EAs (all grades) were as follows: hyponatraemia 62%,
hypokalaemia 40%, hypophosphataemia 32%, hypomagnesaemia 17% and hypocalcaemia
12%. Grade III/IV EAs occurred in 19% of cases. Grade III/IV EAs occurred during the
dose-limiting toxicity window in 8.46% of cases. Diarrhoea was associated with hypomagne-
saemia at all grades (p < 0.001), hyponatraemia at all grades (pZ 0.006) and with G3/G4 hy-
pokalaemia (pZ 0.02). Baseline hypoalbuminaemia and hyponatraemia were associated with
a higher risk of developing other EAs during the trial in the univariate analysis. Patients who
developed grade III/IV EAs during follow-up had an inferior median OS (26 weeks vs 37
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A.H. Ingles Garces et al. / European Journal of Cancer 104 (2018) 32e38 33Conclusion: This is the first study to demonstrate the clinical significance of baseline hypoal-
buminaemia and hyponatraemia, which are predictors of development of other EAs in phase I
patients. Grade III/IV EAs are adverse prognostic factors of OS independent of serum albu-
min levels.
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The development of molecularly target agents for cancer
has resulted in novel adverse events (AEs) correlating
with the mechanism of action of these agents. AEs due
to anti-cancer treatment are a common form of iatro-
genic injury and as molecularly targeted therapies are
generally administered continuously, cumulative toxic-
ities can occur [1,2]. Some AEs caused by this class of
drugs are preventable, but many are unanticipated and
differ with those of other therapeutics such as conven-
tional cytotoxic agents and immunotherapies. The inci-
dence of metabolic toxicities in phase I studies is not well
documented, particularly with regards to electrolyte
abnormalities (EAs) and their consequences. These
toxicities can range from asymptomatic laboratory
findings to symptomatic alterations that can worsen
patients’ quality of life and lead to death.
The treatment for EAs may range from oral supple-
mentation to anti-cancer therapy interruption and
intravenous supplementation, which increases the costs
and risks of drug development. Although they appear
easier to treat compared with other observable toxicities,
the clinical significance of EAs in phase I trials is un-
known. In many clinical trials, asymptomatic laboratory
toxicities are excluded from dose-limiting toxicity (DLT)
assessment as their real clinical significance is doubted.
Nevertheless, these toxicities have significant implica-
tions on resources, including medical assessment time,
laboratory tests, hospital admissions and pharmacy time.
The prognostic significance of some EAs is well
described for several tumour types, such as hypercalcaemia
for breast and kidney cancer and hyponatraemia for small
cell lung cancer [3,4]. However, the incidence, prevalence
and the clinical significance of EAs in oncological phase I
studies are not well documented, and the reasons for
developing these AEs are poorly understood.
Establishing the prevalence of the electrolyte alter-
ations can help to recognise, prevent and optimally
manage them. Furthermore, attempting to understand
the risk factors associated with EAs can help refine in-
clusion/exclusion criteria. To the best of our knowledge,
there is no study exploring the overall risk of EAs in the
phase I cancer setting. We aimed to study the prevalence
of EAs of patients on oncology phase I studies, elucidate
potential risk factors and assess their relevance and
impact in the drug development process of new agents.2. Materials and methods
The principal objective of this study was to determine
the incidence and severity of EAs in a cohort of phase I
cancer patients. Secondary objectives were to evaluate
the association of EAs with other clinical features and
laboratory tests and to estimate the prognostic signifi-
cance of EAs in the phase I setting. Approval to collect
and analyse the data was obtained by applying to the
committee for clinical research at The Royal Marsden
NHS Foundation Trust as a service evaluation (SE541).
A retrospective chart review was performed of 1088
patient cases with solid tumours in 82 phase I clinical
trials consecutively treated from 01/01/2011 to 31/12/2015
in the Drug Development Unit of The Royal Marsden,
who were diagnosed with any type of electrolyte distur-
bance. All data were anonymised before analysis. The
clinical and demographics details including age, sex,
comorbidities, date of last follow-up and date of death
were collected. To be included in this study, patients must
have received at least one dose of the experimental drug.
The phase I trials included dose escalation and expansion
of different classes of drugs, such as protein kinase B
(AKT), poly ADP ribose polymerase (PARP), ataxia-
telangiectasia and Rad3-related (ATR), Mammalian
Target of Rapamycin (mTOR), phosphoinositide-3 ki-
nase (PI3K) and anti-folate receptor inhibitors, used as
single agents and/or in combination.
For this project, hypokalaemia, hyperkalaemia, hypo-
calcaemia, hypercalcaemia, hypomagnesaemia, hyper-
magnesaemia, hypophosphataemia, hyponatraemia and
hypernatraemia were defined and graded according to the
Common Terminology Criteria of Adverse Events
(CTCAE), version 4.03 [5].
Overall survival (OS) was calculated from date of first
treatment to date of death and censored at date of last
follow-up. Cox regression was used to examine the
relationship between OS and baseline characteristics,
treating the occurrence of grade III/IV EAs as a time-
varying covariate. Grade III/IV EAs during the first 4
weeks of the trial were analysed using a logistic regres-
sion model. Backward stepwise regression with a p-value
of 0.2 was used to select variables for a multivariate
logistic regression analysis. Impact of different variables
such as age, sex, comorbidities and death were analysed.
Chi-square and Fisher’s exact test were used to evaluate
the univariate and multivariate analyses along with 95%
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and considered statistically significant if p < 0.05.
3. Results
Patient characteristics are listed in Table 1. Fifty-six
percent of the patient cases were female, and hyperten-
sion was the most common comorbidity (22.4%). Only
5.2% of patients had brain metastases and greater than
92% of patients had normal creatinine. All patients had
performance status 0e1.
The most common emergent EAs of all grades during
the entire course of trials or the termination of data
collection (whichever was first) were as follows: hypo-
natraemia 62%, hypokalaemia 40%, hypo-
phosphataemia 32%, hypomagnesaemia 17% and
hypocalcaemia 12%. Overall, grade III/IV EAs occurred
in 19% of cases. More specifically, grade III/IV EAs
were observed as follows: hyponatraemia 10%, hypo-
phosphataemia 6%, hypokalaemia 5%, hypo-
magnesaemia 1% and hypermagnesaemia 1% (Fig. 1A).
Importantly, during the first 4 weeks of a phase I trial;
typically, the window where the DLT period was
assessed, 92 patients (8.46%) had a grade III/IV EA.
Fig. 1B shows the incidence of EAs during the first 4
weeks of a phase I trial.
A univariate analysis was done to look for risk
factors at baseline (before starting the phase I trial
medication) associated with these EAs (Table 2).
Baseline creatinine values > upper limit of normality
(ULN), baseline values of albumin, sodium and mag-
nesium below ULN were significantly associated with
EAs, and these variables remained significant riskTable 1
Baseline characteristics.
Characteristic N %
Gender
Male 471 43.3
Female 617 56.7
Ethnicity
White 1017 93.5
Black 13 1.2
Asian 19 1.8
Other 19 1.8
Unknown 20 1.8
Brain metastases
No 1032 94.8
Yes 56 5.2
Creatinine> ULN
No 1044 92.3
Yes 84 7.7
Comorbidities
Hypertension 244 22.4
DM 60 5.5
Hypothyroidism 46 4.2
Hyperthyroidism 7 0.6
DVT/PE 174 16.0
Data related to gender, ethnicity and comorbidities thought to be
important in evaluating EAs are described above.factors in multivariate analysis except for magnesium
levels below ULN at baseline and baseline creatinine.
Importantly, age and comorbidities such as brain
metastasis, diarrhoea, hypothyroidism or diabetes were
not significant risk factors on either univariate or
multivariate analysis. This could have implications on
the way in which inclusion/exclusion criteria of phase I
studies are established.
We also studied associations of individual EAs to
other concomitant toxicities. It was found that diar-
rhoea was associated with hypomagnesaemia in all
grades (hazard ratio [HR] 1.78, 1.32e2.39 95% CI,
p < 0.001), with grade III/IV hypokalaemia (HR 1.93,
1.09e3.43 95% CI, p Z 0.02) and with hyponatraemia
in all grades (HR 0.79, 0.67e0.93, 95% CI, p Z 0.006)
as well. Vomiting was also associated with hypo-
magnesaemia in all grades (HR 1.45, 1.08e1.95 95% CI,
p Z 0.01) and grade III/IV hypokalaemia (HR 2.91,
1.62e5.23, 95% CI, p < 0.001). Baseline hypo-
albuminaemia (odds ratio [OR] 0.32, 95% CI 0.20e0.51,
p < 0.001) and hyponatraemia (OR 0.74, 95% CI
0.69e0.80, p < 0.001) are associated with higher risk of
developing other EAs on trial in the univariate analysis.
Patients who developed grade III/IV EAs during the
period of the phase I study had a poorer median OS (26
weeks vs 37 weeks, HR Z 1.61; 95% CI: 1.37e1.90;
p < 0.001) (Fig. 2).4. Discussion
Baseline EAs are common in patients with advanced
cancer participating in phase I trials. However, the
incidence, prevalence and clinical prognostic significance
of EAs in phase I studies are not well documented. To
date and to our knowledge, this is the first detailed
evaluation of electrolyte panel alterations and its im-
plications in cancer care in the phase I setting, providing
data of special relevance to the drug development
process.
Improvement in cancer outcomes has been observed
over the last few decades; however, it has unveiled newer
challenges including different metabolic abnormalities.
It is reported that hypophosphataemia is a frequent
adverse effect of mTOR inhibitors, MET and selective
ALK inhibitors [6,7]. mTOR inhibitors could down-
regulate phosphate carriers in the proximal tubules
along with increased 1,25-dihydroxyvitamin D3 levels in
a preclinical study [6]. Hypomagnesaemia is a common
metabolic abnormality in treatment with monoclonal
antibodies against endothelial growth factor receptor
(EGFR) [6]. A prospective analysis showed defective
renal magnesium reabsorption, which is thought to arise
from the role of EGFR in regulating the activity and
distribution of transepithelial magnesium TRPM6 [6,8].
Despite all this information, we do not have much data
about these EAs with other agents and disturbances of
Table 2
Univariate and multivariate analysis of factors affecting EAs.
Univariate Multivariate
OR 95% CI p-value OR 95% CI p-value
Age (per 10 years) 1.19 0.99e1.42 0.06 1.14 0.94e1.37 0.19
Gender
Male 1 e 0.4 e e e
Female 1.21 0.78e1.87 e e e e
Ethnicity
White 1 e 0.27 e e e
Black 0.94 0.12e7.30 e e e e
Asian 3 0.97e9.25 e e e e
Other 2.11 0.60e7.39 e e e e
Unknown 0.59 0.08e4.48 e e e e
Diarrhoea 0.94 0.59e1.49 0.78
Vomiting 1.46 0.95e2.24 0.08 1.52 0.97e2.38 0.07
Brain Mets 0.83 0.29e2.34 0.72
Creatinine > ULN 2.37 1.28e4.41 0.006 2.73 1.42e5.26 0.003
Comorbidities
Hypertension 1.41 0.87e2.27 0.16 e e e
DM 1.22 0.51e2.91 0.66 e e e
Hypothyroidism 1.03 0.36e2.95 0.95 e e e
DVT 0.94 0.52e1.70 0.83 e e e
Hypercholesterolaemia 1.13 0.47e2.69 0.79 e e e
Osteoporosis 2.44 0.52e11.45 0.26 e e e
Coronary disease 0.45 0.06e3.33 0.43 e e e
Baseline lab results
Creatinine (per 10) 1.06 0.95e1.17 0.3 1.11 0.98e1.24 0.06
Albumin (per 10) 0.32 0.20e0.51 <0.001 0.53 0.32e0.86 0.01
Na 0.74 0.69e0.80 <0.001 0.76 0.70e0.82 <0.001
K 0.73 0.41e1.30 0.28 e e e
Ca 1.88 0.59e5.98 0.29 e e e
P 0.69 0.30e1.58 0.38 e e e
Mg 0.76 0.62e0.93 0.008 e e e
The figures in bold represent statistically significant in both univariate and multivariate analysis.
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anti-cancer target therapies that we have today. The
reasons for developing these side-effects are poorly un-
derstood and many pathophysiologic mechanisms have
been proposed. The relevance of our study is that it
shows that EAs in general are not only a theoretical risk
but also a real and pragmatic issue.
Early diagnosis of EAs and appropriate management
are important and expected to reduce adverse outcomes.
However, the experience of a significant toxic event in a
patient with a poor prognosis has clinical and quality of
life implications. The clinical presentation of EAs is
variable, ranging from asymptomatic to minor mani-
festations such as fatigue, to more serious and life-
threatening manifestations such as cardiac arrhythmia.
Clinicians treating patients in phase I trials should be
able to define the risk associated with experimental
treatments to assist patients in undertaking the decision
to undergo such therapies as patients often underesti-
mate the impact of significant treatment-related toxicity
associated with phase I agents [1].
Although diagnosis of EAs is relatively simple with
routine laboratory assessments on biochemical panels,
identifying the causal mechanism of EAs is moreproblematic. Possible causes in cancer patients include
the use of a large number of concomitant medications,
some of which are known to cause EAs [9,10], as well as
cancer-induced organ dysfunction such as renal
impairment [11], which can also commonly cause EAs.
Malignancy itself is also associated with paraneoplastic
phenomena that manifest as EAs. Well-known cancer-
associated metabolic disturbances include hyper-
calcaemia of malignancy and hyponatraemia induced by
syndrome of inappropriate ADH secretion [12e14].
Hyponatraemia is known to be the most common EA
in clinical practice. It is associated with poor clinical
outcomes such as reduced survival, disability, prolonged
hospital stay and increased hospital costs [12e16].
Published data suggest that hyponatraemia, even when
mild and chronic, represents an economic burden [16].
Therefore, it is not surprising that hyponatraemia is
associated with an increased resource utilisation and
costs [16]. This is an important issue that needs to be
considered as the costs of drug development could be
increased if hyponatraemia and other EAs are under-
estimated. To exemplify this condition, in the United
States of America, the direct medical costs of hypona-
traemia in a general population were estimated to range
Fig. 1. The most common patient cases of electrolyte abnormalities (EAs) in 1088 consecutive patients. (A) The most common emergent
EAs recorded during the entire trial or when the data collection stopped (which ever was earlier). (B) The most common emergent EAs
during the first 4 weeks of clinical trials, which are typically used to define dose-limiting toxicities.
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data, hyponatraemia is often poorly considered if not
ignored, even in a cancer population, as well as other
EAs which we have no estimation of their social burden.As reported previously, electrolytic disorders are com-
mon in cancer patients andmay worsen patient prognosis.
Hyponatraemia in small-cell lung is well correlated with
prognosis and survival [12,15,18]. Few studies have
Fig. 2. Overall survival of patients with and without grade III/
IV EAs. A KaplaneMeier estimate of survival of patients who did
and did not experience a grade III/IV EA during the entire period
of the trial or when data collection was stopped (whichever was
earlier). HR, hazard ratio; CI, confidence interval; IQR, inter-
quartile range; EA, electrolyte abnormality.
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but it has been shown that the normalisation of sodium
concentration improved OS and progression-free survival
(PFS) in this population [19]. However, our study is the
first one to demonstrate the clinical significance of baseline
hyponatraemia with development of other EAs and that
grade III/IVEAs are significant adverse prognostic factors
of OS in phase I patients with different tumour types.
Thus, sodium is a very important parameter that could be
added to validated prognostic scores used to select patient
for clinical trials.
In the multivariate analysis, comorbidities such as
hypertension, diabetes or hypothyroidism were not
significantly associated with EAs during phase I trials. It
is important to highlight that, contrary to expectations
[20], in the analysis of our data, presence of brain me-
tastases had no clinical significant association with EAs,
including hyponatraemia. This is probably because few
patients with brain metastases were enrolled on trials as
this condition is usually an exclusion criterion for phase
I studies.
In phase I trials, a strong association between the
EAs hypokalaemia/hypomagnesaemia and the AEs
vomiting/diarrhoea was demonstrated. Although this
association is well known regardless of the context
[21,22], our study shows that those EAs may be better
objective measures of drug-related toxicity than the
current CTCAE criteria for patient-reported diarrhoea/
vomiting, as they are highly subjective and open to recall
bias. This could have direct clinical implications when
dealing with drugs known to cause these AEs, and
hypokalaemia/hypomagnesaemia could be used as sur-
rogate markers of gastrointestinal toxicities.
Our descriptive epidemiological study has some
important advantages in its design: using data frompatients enrolled into phase I clinical trials, it was
reassured that the studied population would not have
major organ dysfunction as baseline and high-quality
data without missing values were available leading to
reliable results. Another strength of this study is the
large sample size; therefore, EAs could be investigated
and conclusions could be drawn accordingly. However,
despite the large size of this cohort, some limitations
need to be considered. This is a retrospective study
with a heterogeneous cohort not only in terms of
tumour types but also the class of drugs and their
combinations used in different phase I trials. More-
over, the studies were conducted in a specialised phase
I cancer centre, so it does not reflect the general patient
population but, on the other hand, the numbers are
robust enough to allow conclusions in this very specific
population. The patient cases collected were on 82
different clinical trials. While it would have been
interesting to compare EAs between different drugs or
different classes of drugs, getting permission to do so
from sponsors in all cases was thought to be imprac-
tical and not feasible.
Currently, most phase I studies do not have cutoffs
for EAs in their exclusion criteria, but their focus is on
haematological, renal and liver function tests. Our data
suggest that abnormal baseline EAs not only predict
AEs related to EAs but also prognosis and should be
considered while establishing inclusion and exclusion
criteria. Similarly, baseline albumin has been recognised
as predictor for survival and AEs [23].
There is no specific test that will establish the cause of
drug-induced metabolic alterations, but if any EA is
recognised, differential diagnosis and the liaison be-
tween target-therapy and electrolyte alteration could be
made. Establishing the diagnosis of drug toxicity is
important, as it may have significant implications for
clinical care, as measures for prevention and correct
management will be taken and the discontinuation of an
agent on suspicion alone could be avoided and the pa-
tient would not be deprived of a potentially life-
prolonging treatment. EAs can be another tool to help
how to improve patient selection for clinical trials and to
reduce the likelihood of expensive failures during the
drug development process. Given the risk and the high
incidence of EAs observed in this study, careful moni-
toring and early treatment are proposed as EAs can
worsen the performance status and patient’s quality of
life. These results can improve the safety of phase 1
clinical trials and also it will be a useful tool for future
reference in medical research as a definitive study of EAs
in phase I clinical trials setting.
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